{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:12:26Z","timestamp":1762272746406,"version":"3.40.5"},"reference-count":67,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Perhaps the most important lesson learned from the COVID\u201019 pandemic is that of preparedness. Enhanced surveillance systems for early threat detection will be crucial to maximizing response time for implementation of public health measures and mobilization of resources in containing an emerging pandemic. Recent outbreaks have been dominated by viral pathogens, with RNA respiratory viruses being the most likely to have pandemic potential. These should therefore be a preparedness priority. Tools in the areas of virology, drug discovery, clinical pharmacology, translational medicine and pharmacometrics should be considered key components in the rapid identification and development of existing and novel interventions for a pandemic response. Prioritization of therapeutics should be based on in vitro activity, likelihood of achieving effective drug concentrations at the site of action, and safety profile at the doses that will be required for clinical efficacy. Deployment strategies must be tailored to the epidemiology of the disease, and the adequacy of the response should be re\u2010evaluated in view of evolving epidemiological factors. An interdisciplinary framework integrating drug pharmacology, viral kinetics, epidemiology and health economics could help optimize the deployment strategy by improving decision\u2010making around who to treat, when to treat, and with what type of intervention for optimal outcomes. Lastly, while an effective vaccine will ultimately end a pandemic, antiviral drug intervention guided by clinical pharmacology principles will continue to play a critical role in any pandemic response.<\/jats:p>","DOI":"10.1111\/bcp.14859","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T21:08:27Z","timestamp":1618520907000},"page":"3398-3407","source":"Crossref","is-referenced-by-count":3,"title":["Blueprint for pandemic response: Focus on translational medicine, clinical pharmacology and pharmacometrics"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0888-2936","authenticated-orcid":false,"given":"Jasmine","family":"Davda","sequence":"first","affiliation":[{"name":"Certara  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP), Office of Translational Sciences (OTS) Center for Drug Evaluation and Research, U.S. Food and Drug Administration  Silver Spring MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6003-0805","authenticated-orcid":false,"given":"Patrick F.","family":"Smith","sequence":"additional","affiliation":[{"name":"Certara  Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06536"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1596\/978-1-4648-0527-1_ch17"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/82_2019_176"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/9781555818432.ch6"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2299-6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.05.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2558-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00967-18"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12797"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1909"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14314"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa623"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1879"},{"key":"e_1_2_6_15_1","unstructured":"USFDA.Coronavirus (COVID\u201019) Update: FDA Takes Additional Action to Harness Real\u2010World Data to Inform COVID\u201019 Response Efforts.2020;https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/coronavirus\u2010covid\u201019\u2010update\u2010fda\u2010takes\u2010additional\u2010action\u2010harness\u2010real\u2010world\u2010data\u2010inform\u2010covid\u201019. Accessed September 22 2020."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.03.019"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01814-20"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01378-w"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015301"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138003"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1271-9"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/57.3.259"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10044"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.10.008"},{"key":"e_1_2_6_28_1","unstructured":"FDA.Letter of Authorization Reissuance of Convalescent Plasma EUA November 30 2020.2020;https:\/\/www.fda.gov\/media\/141477\/download"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbaa020"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.23684"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00350-19"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0564-y"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.02.021"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.24415"},{"key":"e_1_2_6_35_1","unstructured":"FDA.Emergency Use Authorization for emergency use of casirivimab and imdevimab.2020;https:\/\/www.fda.gov\/media\/143891\/download"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0827"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5883"},{"key":"e_1_2_6_43_1","unstructured":"BorasB JonesRM AnsonBJ et al.Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID\u201019.bioRxiv: the preprint server for biology.2020."},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30226-5"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202008-3148LE"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70920-X"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195"},{"key":"e_1_2_6_50_1","unstructured":"Agency UMaHPR.Conditions of Authorisation for Pfizer\/BioNTech COVID\u201019 vaccine.2020;https:\/\/www.gov.uk\/government\/publications\/regulatory\u2010approval\u2010of\u2010pfizer\u2010biontech\u2010vaccine\u2010for\u2010covid\u201019\/conditions\u2010of\u2010authorisation\u2010for\u2010pfizerbiontech\u2010covid\u201019\u2010vaccine"},{"key":"e_1_2_6_51_1","unstructured":"Canada H.Regulatory Decision Summary \u2010 Pfizer\u2010BioNTech COVID\u201019 Vaccine.2020;https:\/\/covid-vaccine.canada.ca\/info\/regulatory-decision-summary-detailTwo.html?linkID=RDS00730"},{"key":"e_1_2_6_52_1","unstructured":"USFDA.Pfizer\u2010BioNTech COVID\u201019 Vaccine EUA Letter of Authorization.2020;https:\/\/www.fda.gov\/media\/144412\/download"},{"key":"e_1_2_6_53_1","unstructured":"FDA.Moderna COVID\u201019 Vaccine EUA Letter of Authorization.2020;https:\/\/www.fda.gov\/media\/144636\/download. Accessed 19 December 2020."},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0075-3"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12790"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12824"},{"key":"e_1_2_6_58_1","unstructured":"Health NIo.Accelerating COVID\u201019 Therapeutic Interventions and Vaccines (ACTIV).2020;https:\/\/www.nih.gov\/research-training\/medical-research-initiatives\/activ. Accessed September 28 2020."},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.12688\/gatesopenres.13146.1"},{"key":"e_1_2_6_60_1","unstructured":"Administration UFaD.COVID\u201019: Developing Drugs and Biological Products for Treatment or Prevention. In:2020."},{"key":"e_1_2_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064198"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16585-y"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007626510002"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04017"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13229"},{"key":"e_1_2_6_67_1","unstructured":"Ellume.COVID\u201019 Home Test.2020;https:\/\/www.ellumehealth.com\/products\/consumer-products\/covid-home-test. Accessed 3 December 2020."},{"key":"e_1_2_6_68_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268818000158"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:44:14Z","timestamp":1693345454000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/bcp.14859"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14859","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"type":"print","value":"0306-5251"},{"type":"electronic","value":"1365-2125"}],"subject":[],"published":{"date-parts":[[2021,5,6]]}}}